The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Overall and progression-free survival with everolimus, temsirolimus, or sorafenib as second targeted therapies for metastatic renal cell carcinoma: A retrospective U.S. chart review.
Hongbo Yang
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Novartis
Michael K.K. Wong
Consultant or Advisory Role - Merck; Novartis; Pfizer
Honoraria - Merck; Novartis; Pfizer
James E. Signorovitch
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Novartis
Xufang Wang
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Zhimei Liu
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Nathan S. Liu
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Novartis
Zhengyun Qi
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Novartis
Daniel J. George
Consultant or Advisory Role - Bayer; Novartis; Pfizer
Honoraria - Novartis; Pfizer
Research Funding - Novartis; Pfizer